Pretreatment performance status and nutrition are associated with early mortality of locally advanced head and neck cancer patients undergoing concurrent chemoradiation

详细信息    查看全文

• 作者：Pei-Hung Chang (1)
  Kun-Yun Yeh (1)
  Jen-Seng Huang (1)
  Chien-Hong Lai (1)
  Tsung-Han Wu (1)
  Yii-Jenq Lan (1)
  Jason Chien-Sheng Tsai (2)
  Eric Yen-Chao Chen (2)
  Shih-Wei Yang (3)
  Cheng-Hsu Wang (1) (4)
  
• 关键词：Head and neck cancer ; Concurrent chemoradiation ; Risk factors ; Early death ; Malnutrition
• 刊名：European Archives of Oto-Rhino-Laryngology
• 出版年：2013
• 出版时间：May 2013
• 年：2013
• 卷：270
• 期：6
• 页码：1909-1915
• 全文大小：182KB
• 参考文献：1. Haddad RI, Shin DM (2008) Recent advances in head and neck cancer. N Engl J Med 359:1143-154 CrossRef
  2. De Luis DA, Izaola O, Aller R (2007) Nutritional status in head and neck cancer patients. Eur Rev Med Pharmacol Sci 11:239-43
  3. Wang CH, Wang HM, Pang YP et al (2012) Early nutritional support in non-metastatic stage IV oral cavity cancer patients undergoing adjuvant concurrent chemoradiotherapy: analysis of treatment tolerance and outcome in an area endemic for betel quid chewing. Support Care Cancer 20:1169-174 CrossRef
  4. Browman GP, Hodson DI, Mackenzie RJ et al (2001) Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 23:579-89 CrossRef
  5. Pignon JP, le Maitre A, Bourhis J (2007) Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 69:S112–S114 CrossRef
  6. Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949-55
  7. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-098 CrossRef
  8. Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-944 CrossRef
  9. Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-952 CrossRef
  10. Bernier J, Cooper JS, Pajak TF et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27:843-50 CrossRef
  11. Ang KK, Harris J, Garden AS et al (2005) Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-4. J Clin Oncol 23:3008-015 CrossRef
  12. Staar S, Rudat V, Stuetzer H et al (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy—results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:1161-171 CrossRef
  13. Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-8 CrossRef
  14. Abitbol AA, Sridhar KS, Lewin AA et al (1997) Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/?granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Cancer 80:266-76 CrossRef
  15. Calais G, Alfonsi M, Bardet E et al (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-086 CrossRef
  16. Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-715 CrossRef
  17. van Wayenburg CA, Rasmussen-Conrad EL, van den Berg MG et al (2010) Weight loss in head and neck cancer patients little noticed in general practice. J Prim Health Care 2:16-1
  18. Beisel WR (1996) Nutrition in pediatric HIV infection: setting the research agenda. Nutrition and immune function: overview. J Nutr 126:2611S-615S
  19. Chandra RK (1991) 1990 McCollum Award lecture. Nutrition and immunity: lessons from the past and new insights into the future. Am J Clin Nutr 53:1087-101
  20. Chandra RK (1999) Nutrition and immunology: from the clinic to cellular biology and back again. Proc Nutr Soc 58:681-83 CrossRef
  21. Phillips RS, Enwonwu CO, Falkler WA (2005) Pro- versus anti-inflammatory cytokine profile in African children with acute oro-facial noma (cancrum oris, noma). Eur Cytokine Netw 16:70-7
  22. Pugliese MT (1990) Endocrine function adaptations in undernutrition. World Rev Nutr Diet 62:186-11
  23. Datema FR, Ferrier MB, Baatenburg de Jong RJ (2011) Impact of severe malnutrition on short-term mortality and overall survival in head and neck cancer. Oral Oncol 47:910-14 CrossRef
  24. Esteve J, Riboli E, Pequignot G et al (1996) Diet and cancers of the larynx and hypopharynx: the IARC multi-center study in southwestern Europe. Cancer Causes Control 7:240-52 CrossRef
  25. van den Berg MG, Rasmussen-Conrad EL, Gwasara GM, Krabbe PF et al (2006) A prospective study on weight loss and energy intake in patients with head and neck cancer, during diagnosis, treatment and revalidation. Clin Nutr 25:765-72 CrossRef
  26. Pajak TF, Laramore GE, Marcial VA et al (1991) Elapsed treatment days—a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 20:13-0 CrossRef
  27. Brookes GB (1985) Nutritional status—a prognostic indicator in head and neck cancer. Otolaryngol Head Neck Surg 93:69-4
  28. Ravasco P, Monteiro-Grillo I, Vidal PM et al (2004) Cancer: disease and nutrition are key determinants of patients-quality of life. Support Care Cancer 12:246-52 CrossRef
  29. Regueiro CA, Aragon G, Millan I et al (1994) Prognostic factors for local control, regional control and survival in oropharyngeal squamous cell carcinoma. Eur J Cancer 30A:2060-067 CrossRef
  30. Bachelot T, Ray-Coquard I, Catimel G et al (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11:151-56 CrossRef
  31. Borg C, Ray-Coquard I, Philip I et al (2004) CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 101:2675-680 CrossRef
  32. Claude L, Perol D, Ray-Coquard I et al (2005) Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 76:334-39 CrossRef
  33. Huang JJ, Jiang WQ, Lin TY et al (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 22:149-55 CrossRef
  34. Ray-Coquard I, Ghesquiere H, Bachelot T et al (2001) Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 85:816-22 CrossRef
  35. Riesco A (1970) Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25:135-40 CrossRef
  36. Muss HB, Berry DA, Cirrincione C et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 25:3699-704 CrossRef
  
• 作者单位：Pei-Hung Chang (1)
  Kun-Yun Yeh (1)
  Jen-Seng Huang (1)
  Chien-Hong Lai (1)
  Tsung-Han Wu (1)
  Yii-Jenq Lan (1)
  Jason Chien-Sheng Tsai (2)
  Eric Yen-Chao Chen (2)
  Shih-Wei Yang (3)
  Cheng-Hsu Wang (1) (4)
  
  1. Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung and Chang Gung University, College of Medicine, 200, Lane 208, Jijin 1st Road, Keelung, 20445, Taiwan
  2. Department of Radiation Oncology, Chang Gung Memorial Hospital, Keelung and Chang Gung University, College of Medicine, 200, Lane 208, Jijin 1st Road, Keelung, 20445, Taiwan
  3. Department of Otolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital, Keelung and Chang Gung University, College of Medicine, 200, Lane 208, Jijin 1st Road, Keelung, 20445, Taiwan
  4. Cancer Center, Chang Gung Memorial Hospital, Keelung, Taiwan
  
• ISSN：1434-4726

文摘

Unexpected fatal events in patients with head and neck cancers undergoing concurrent chemoradiation therapy are a clinical concern. Malnutrition, which is reported frequently in head and neck cancer patients, are associated with immunity derangement. The purpose of this study was to identify risk factors for early death of patients undergoing chemoradiation. We retrospectively analyzed the records of 194 stage III, IVA, and IVB head and neck cancer patients who were treated with chemoradiation between 2007 and 2009. We defined early death as death while receiving chemoradiation or within 60?days of treatment completion. Risk factors for early death were tested using univariate and multivariate analyses. Fourteen patients (7.2?%) experienced early death, 78.6?% of whom died of infection. Univariate analysis revealed significant correlations between early death and several pretreatment variables, including Eastern Cooperative Oncology Group performance status (PS) >1, hemoglobin <10?g/dL, albumin <3?g/dL, body mass index (BMI) <19?kg/m2, and peripheral blood total lymphocyte count <700/μL. Multivariate analysis showed that PS >1, BMI <19?kg/m2, and peripheral blood total lymphocyte count <700/μL were independent variables associated with early death. Poor performance status and malnutrition before chemoradiation independently predict early death in locally advanced head and neck cancer patients undergoing chemoradiation. Cautious management of head and neck cancer patients with these risk factors is required throughout chemoradiation period.